Marinus Pharmaceuticals Inc expected to post a loss of 41 cents a share - Earnings Preview

* Marinus Pharmaceuticals Inc is expected to show a rise in quarterly revenue when it reports results on November 5 (estimated) for the period ending January 1 0001

* The Radnor Pennsylvania-based company is expected to report a 28.3% increase in revenue to $9.418 million from $7.34 million a year ago, according to the mean estimate from 10 analysts, based on LSEG data.

* ​LSEG's mean analyst estimate for Marinus Pharmaceuticals Inc is for a loss of 41 cents per share.

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy," 7 "hold" and no "sell" or "strong sell."

* The mean earnings estimate of analysts was unchanged in the last three months. ​

* Wall Street's median 12-month price target for Marinus Pharmaceuticals Inc is $2.00​, above​ its last closing price of $0.30. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI

ENDING ARTESTIMAT ESTIMATE MET, SE %

E® MISSED

Jun. 30 2024 -0.59 -0.59 -0.60 Missed -1.8

Mar. 31 2024 -0.66 -0.66 -0.68 Missed -2.8

Dec. 31 2023 -0.62 -0.62 -0.74 Missed -18.8​

Sep. 30 2023 -0.65 -0.66 -0.61 Beat 7.7

​​Jan. -0.69 -0.72 -0.61 Beat 14.9

1 0001

Mar. 31 2023 -0.71 -0.72 -0.67 Beat 7.3​

Dec. 31 2022 -0.66 -0.70 -0.76 Missed -9.1

Sep. 30 2022 0.54 0.47 -0.94 Missed -301.2

This summary was machine generated November 1 at 14:14 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)